Association Between Fish Consumption and Minimal Disease Activity in Patients With Rheumatoid Arthritis Receiving Molecular-Targeted Therapies.

Authors

Masato Tarumi, Olga Amengual, Míriam Navidad, Yotaro Oki, Mitsutaka Yasuda, Yui Kosumi, Shuhei Takeyama, Masaru Yoshimura, Keita Ninagawa, Kuniyuki Aso, Ryo Hisada, Hiroyuki Nakamura, Michihito Kono, Yuichiro Fujieda, Masaru Kato, Akinobu Nakamura, Satomi Kumagai, Rafael Cáliz, Tatsuya Atsumi

Published in

International journal of rheumatic diseases. Volume 29. Issue 8. Pages e70834.

Abstract

Diet may influence the clinical course of rheumatoid arthritis (RA). Consumption of fish, the main source of n-3 polyunsaturated fatty acids (PUFAs), has been linked to decreased disease activity. We investigated the association between fish intake and disease activity in two different cohorts of RA patients receiving molecular-targeted therapies.
This retrospective cross-sectional study included RA patients treated with biologics or Janus kinase inhibitors at Hokkaido University Hospital (Japan) and Virgen de las Nieves Hospital (Spain). Patients completed the validated brief-type self-administered diet history questionnaire (BDHQ, used with permission) and a custom-designed detailed fish frequency questionnaire (DFFQ). Demographic, clinical, and laboratory data were obtained from medical records. Minimal disease activity (MDA) was defined as DAS28-ESR < 2.6 and DAS28-CRP < 2.4. Group comparisons and multivariate logistic regression analyses were performed.
In the Japanese cohort of 205 RA patients, 59% of patients met MDA criteria. Patients with MDA had a higher estimated daily intake of n-3 PUFAs than those with non-MDA. Multivariate logistic regression analysis identified weekly intake of n-3 PUFA-rich fish as an independent factor associated with MDA. In the Spanish RA cohort of 74 patients, 37% met MDA criteria. No significant differences in n-3 PUFA intake or fish consumption were observed between MDA and non-MDA groups.
Consumption of n-3 PUFA-rich fish was associated with MDA in patients with RA receiving molecular-targeted therapies.

PMID:
42628963
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.